2020
Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis
Perry RJ, Zhang D, Guerra MT, Brill AL, Goedeke L, Nasiri AR, Rabin-Court A, Wang Y, Peng L, Dufour S, Zhang Y, Zhang XM, Butrico GM, Toussaint K, Nozaki Y, Cline GW, Petersen KF, Nathanson MH, Ehrlich BE, Shulman GI. Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis. Nature 2020, 579: 279-283. PMID: 32132708, PMCID: PMC7101062, DOI: 10.1038/s41586-020-2074-6.Peer-Reviewed Original ResearchConceptsHepatic steatosisType 2Nonalcoholic fatty liver diseaseDiet-induced hepatic steatosisFatty liver diseasePlasma glucagon concentrationsHepatic adipose triglyceride lipaseHepatic acetyl-CoA contentHepatic glucose productionRatio of insulinHepatic glucose metabolismInositol triphosphate receptorAdipose triglyceride lipaseMitochondrial oxidationMitochondrial fat oxidationGlucose intoleranceLiver diseaseGlucagon concentrationsInsulin resistancePortal veinAcetyl-CoA contentHepatic lipolysisGlucagon biologyGlucose metabolismKnockout miceThe Impact of Obesity on Tumor Glucose Uptake in Breast and Lung Cancer
Leitner BP, Perry RJ. The Impact of Obesity on Tumor Glucose Uptake in Breast and Lung Cancer. JNCI Cancer Spectrum 2020, 4: pkaa007. PMID: 32368718, PMCID: PMC7190208, DOI: 10.1093/jncics/pkaa007.Peer-Reviewed Original ResearchBody mass indexTumor glucose uptakeLung cancerGlucose uptakeGlucose metabolismNon-small cell lung cancerHigher body mass indexObesity-cancer linkImpact of obesityCell lung cancerSquamous cell carcinomaSoft tissue sarcomasAltered glucose metabolismPoor clinical prognosisTumor glucose metabolismMass indexPoor outcomeTissue sarcomasCell carcinomaTomography/Clinical prognosisBreast cancerProtective effectObesityCancer
2019
SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia
Nasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer & Metabolism 2019, 7: 10. PMID: 31867105, PMCID: PMC6907191, DOI: 10.1186/s40170-019-0203-1.Peer-Reviewed Original ResearchControlled-release mitochondrial protonophoreInsulin-lowering agentsTumor growthSodium-glucose cotransporter 2 inhibitorsObesity-cancer connectionSustained weight lossCotransporter 2 inhibitorsObesity-associated cancersSubcutaneous insulin infusionInsulin-lowering effectTumor glucose uptakeBreast tumor growthMultiple comparisonsMultiple tumor typesSGLT2 inhibitionSGLT2 inhibitorsObese miceInsulin infusionColon cancer progressionTherapeutic approachesMouse modelBonferroni multiple comparisonsGlucose metabolismColon cancerHyperinsulinemia